Autres langues Amgen Inc. Buenos Aires S.E.

Actions

AMGN

ARDEUT110665

Cours en clôture Buenos Aires S.E. Autres places de cotation 00:00:00 14/06/2024			Varia. 5j.	Varia. 1 janv.
12 568 ^ARS	-1,15%		-5,90%	+34,65%

14/06	Amgen Inc. annonce que la Food and Drug Administration américaine approuve le Blincyto	CI
14/06	Mise à jour sectorielle : Les actions du secteur de la santé sont plus molles vendredi après-midi	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	14/06
Amgen : Continues to Propel BiTE® Technology Innovation	14/06
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	14/06
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	14/06
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	14/06
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	13/06
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024	12/06
Amgen : Leaders Hail Southern California’s Emergence as Biotech Innovation Hub	11/06
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	11/06
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar	11/06
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE	06/06
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	05/06
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	05/06
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD	05/06
Amgen's drug meets main goal in late-stage study for rare disease	05/06
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)	05/06
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)	05/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Amgen Inc. Buenos Aires S.E.

Actions

AMGN

ARDEUT110665

Autres langues

Filtres